MedTrace Logo

FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients

NCT02704468 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-07-19

No results posted yet for this study

Summary

Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness. The cardio-ankle vascular index (CAVI) is a new index of overall stiffness and can estimated the risk of atherosclerosis.

Fibroblast growth factor 21 (FGF-21) is a metabolic regulator that plays important role in cardiac remodeling elevated FGF-21 have been reported in coronary heart disease or carotid artery plaque and could be biomarkers for atherosclerosis disease Investigators aimed to study the association between CAVI and FGF-21 and their relations to various parameters that can contribute to cardiovascular disease eg. homocysteine Echocardiogram findings and other traditional basic factors.

Conditions

  • Vascular Stiffness

Interventions

OTHER

CAVI and FGF-21

FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness

Sponsors & Collaborators

  • Bangkok Metropolitan Administration Medical College and Vajira Hospital

    lead OTHER_GOV

Principal Investigators

  • Thananda Trakarnvanich, M.D. · Bangkok metropolitan administration medical college of vajira hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704468 on ClinicalTrials.gov